References
- Parkin DM . Cancer in indigenous Africans burden, distribution and trends. Lan Oncol 2008;9(7):683–692.10.1016/S1470-2045(08)70175-X
- Sokoll LJ . Tumour Markers. In: Wurm-Cutter E , editor. Tietz textbook of clinical chemistry and molecular diagnostics. Atlanta:Elsevier; 2005. p. 617–667.
- Hoffman RM . Using the free-to-total prostate-specific antigen ratio to detect prostate cancer in men with non-specific elevations of prostate-specific antigen level. J Gen Int Med. 2000;15: 739–748.10.1046/j.1525-1497.2000.90907.x
- Omar J . A pilot study on percent free prostate specific antigen as an additional tool in prostate cancer screening. Malaysian J Med Sci 2008;16(1): 44–47.
- Mccudden CR . Circulating tumour markers: Basic concepts and clinical application. In: Troy D , editor. Clinical Chemistry Principles, Techniques and Correlation. Philadelphia, PA : Lippincot and Williams; 2005. p. 664–679.
- Musrap W . Prostate specific antigen as a marker of hyperandrogenism in women and its clinical implications for antidoping. Clin Chem. 2016;62(8):1066–1074.10.1373/clinchem.2016.256198
- Adhyam M . A review on the clinical utility of PSA in cancer prostate. Indian J Surg Oncol 2012;3(2): 120–129.10.1007/s13193-012-0142-6
- Southwick PC . The role of free PSA in the detection of prostate cancer. J Lab Med 2001;32(5): 259–262.10.1309/06E3-4LG5-KYEG-FGAC
- Prcic A , Begic E , Hiros M . Usefulness of total PSA value in prostate diseases diagnosis. Acta Inform Med. 2016;24(3): 156–161. doi:10.5455/aim.2016.24.156-161.
- Carter HB . Prostate cancers in men with low PSA levels—must we find them? N Engl J Med. 2004;350: 2292.10.1056/NEJMe048003
- Loeb S . What to do with an abnormal PSA test. Oncol. 2008;13: 299–305.10.1634/theoncologist.2007-0139
- Catalona WJ . Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. J Am Med Assoc. 1998;279: 1542–1547.10.1001/jama.279.19.1542
- Kilic S . Determination of the site of metabolism of total, free and complexed prostate specific antigen. Urology 1998;52(3): 470–473.10.1016/S0090-4295(98)00208-8
- Agnihotri S , Mittal RD , Kapoor R , Mandhani A . Raising cut-off value of prostate specific antigen (PSA) for biopsy in symptomatic men in India to reduce unnecessary biopsy. Indian J Med Res. 2014;139(6):851–856.
- South African National Cancer Registry. Johannesburg: Cancer in South Africa; 2012 [cited 2017 Oct 25]. Available from: www.ncr.ac.zawww.ncr.ac.
- Thompson IM , Donna K . Prevalence of prostate cancer among men with prostate specific antigen level<4.0 ng/ml. N. Engl J Med. 2004;350: 2239–2246.10.1056/NEJMoa031918
- Nishio R . Metastatic prostate cancer with normal level of serum prostate specific antigen. Int Urol Nephrol J. 2003;35: 189–192.10.1023/B:UROL.0000020306.08275.49
- Ibrahim E . Incidence of carcinoma of the prostate in patients with normal prostate specific antigen following prostatectomy. Glob J Med Res Surg Cardiovas Syst. 2013;13(3).